I spoke to Michael Klotsman, the entrepreneur behind the pilot study of GLP-1 drugs or "Pawzempic in fat cats: "We genuinely believe that we have an opportunity to increase life spans across the board by an average of one to three years," he says.
Read more on @inc.com
www.inc.com/chloe-aiello...
inc.com
How This Founder's Old Dog Inspired a 10-Year Cat Ozempic Odyssey
Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments for pets.